[1] Halioua B and Malkkin J E. Epidemiology of Gential
Herpes -Recent Advances. Eur. J. Dermatol. 1999
(Apr-May);9[3] 177-184.
[2] Corey L and Handsfield H H. Gential Herpes and
Public Health: Affressing a Global Problem. JAMA 2000 (Feb);
283[6] 791-794.
[3] Scopp,Irwin Walter. Oral Medicine: A Clinical
Approach with Basic Science Correlation 1969; 87-89
[4] Mikloska Z, Danis V A, Adams S, Lloyd A R, Adrian
D L, and Cunningham A L. In Vivo Production of Cytokines
and Beta (C-C)
Chemokines In Human Recurrent Herpes Simplex Lesions- Do Herpes Simplex
Virus - Infested
Keratinocytes
Contribute To Their Production? JID 1998;177(April) 827-838.
[5] Darby M L and Bushee E J. Mosby's: Comprehensive
Review Of Dental Hygiene.Second Edition 1991; 207-208,
258, 268-269.
[6] Rafttery M J, Behrens C K, Muller A, Krammer
P H, Walczak H, and Schonrich G. Herpes Simplex Virus Type I
Infection of
Activated Cytotoxic T Cells: Induction of Fratricide as a Mechanism of
Viral Immune Evasion. J. Exp.
Med. 1999;190[8]
1103-1113.
[7] Hsiung G D, Diagnostic Virology: An Illustrated
Handbook. Revised and Enlarged Edition. 1973;127-137.
[8] Ackermann H W and Berthiaume L. Atlas of Virus
Diagrams. CRC Press. 36-41.
[9] Ackermann H W, Berthiaume L, and Tremblay M.
Virus Life in Diagrams. CRC Press 1998; 50-59.
[10] MazzoneH M. CRC Handbook of Viruses: Mass Molecular Weight
Values and Related Properties. CRC Press. 149.
[11] Fields B N, Knipe D M, et al. Fundamental Virology-2nd
Edition 1991; 7-93, 219-272, 841-899.
[12] Nicola A V, Willis S H, Naidoo N N, Eisenberg R J, and
Cohen G H. Structure-Function Analysis of Soluable
Forms of Herpes
Simplex Virus Glycoprotien D. J. Virol.1996(March);3815-3822.
[13] Avitable E, Ward P L, Lazzaro C D, Torrisl M R, Roizman
B, and Campadelli-Fiume G. The Herpes Simplex UL20
Protein Compensates
for the Differential Disruption of Exocytosis of Virions and Viral Membrane
Glycoproteins
Associated with
Fragmantation of the Golgi Apparatus. J. Virol. 1994 (July);7397-7405.
[14] Roller R J and Herold B C. Characterization of a BHK (TK-)
Cell Clone Resistant to Postattachment Entry by
Herpes Simplex Virus
Types 1 and 2. J. Virol. 1997 (May);5805-5813.
[15] Tal-Singer R, Peng C, Ponce De Leon M, Abrams W R, Banfield
B W, Tufaro F, Cohen G H, and Eisenberg R J.
Interaction
of Herpes Simplex Virus Glycoprotein gC with Mammalian Cell Surface Molecules.
J. Virol. 1995 (July);
4471-4483.
[16] Mikloska Z and Cunningham A L. Herpes Simplex Virus Type
1 Glycoproteins gB, gC and gD are Major Targets for
CD4 T-Lymphocyte Cytotoxicity
in HLR-DR expressing Human Epidermal Keratinocytes. J. Gen.Virol. 1998;79,
353-361.
[17] Koelle D M, Corey L, Burke R L, Eisenberg R J, Cohen G
H, Pichyangkura R, and Triezenberg S J. Antigenic
Specificities
from Recurrent Gential Herpes Simplex Virus Type 2 Lesions. J. Virol. 1994
(May); 2803-2810.
[18] Kuby J. Immunology - 3rd Edition 1997; 374-375, 328, 336-352,
318-320.
[19] Walker J and Leib D A. Protection from Primary Infection
and Establishment of Latency by Vaccination with Herpes
Simplex Virus
Type I Recombinant Deficient in the Viron Host Shutoff (vhs) Function.
Vaccine 1998; 16[1], 1-5.
[20] Neumann L, Krass W, Uebel S, Jung G, and Tampe R. The Active
Domain of The Herpes Simplex Virus Protien
ICP47: A Potent
Inhibitor of The Transporter Associated with Antigen Processing (TAP).
J. Mol. Biol. 1997; 272,
484-492.
[21] Galocha B, Hill A, Barnett B C, Dolan A, Raimondi A, Cook
R F, Brunner J, McGeoch, and Ploegh L. The
Active Site
Of ICP47, a Herpes Simplex Virus - Encoded Inhibitor of the Major
Histocompatibility Complex
(MHC)-encoded
Peptide Transporter Associated with Antigen Processing (TAP), Maps of the
NH(2)-terminal 35
Residues. J.
Exp. Med. 1997(May);185[9], 1565-1572.
[22] Freidman H M, Wang L, Fishman N O, Lambris J D, Eisenberg
R J, Cohen G, and Lubinski J. Immune Evasion
Properties of
Herpes Simplex Virus Type I Glycoprotein gC. J. Virol. 1996 (July); 4253-4260.
[23] Nagashunmugam T, Lubinski J, Wang L, Goldstein L T, Weeks
B S, Sundaresan P, Kang E H, Dubin G, and Friedman
H M. In Vivo
Immune Evasion Mediated by the Herpes Simplex Virus Type I Immunoglobulin
G Fc Receptor. J. Virol.
1998 (July);
5351-5359.
[24] Stanberry L R. Control of STDs--the Role of Prophylactic
Vaccines against Herpes Simplex Virus. Sex Transm. Inf.
1998;74, 391-394
[25] http://ashastd.org/herpes/hrc/educate.html
[26] http://www.henderson-morley.com/research/skinner.html
[27] http://www.henderson-morley.com/research/skinner.html
[28] http://www.homestead.com/HerpesNews/skinnervaccine.html
[29] http://www.newsfile.com/homepage/092898pr.htm#A5
[30] http://www.homestead.com/HerpesNews/LupidonVaccine.htmlSame
as 29 both shoppers
[31] http://dyred.sureste.com/herpes/
[32] http://www.niaid.nih.gov/factsheets/herpesvac.htm
[33] http://www.reach4life.com/lysine.html
[34] http://herpes.com/Treatment.shtml
[35] Vaccine table & PREPS --http://www.henderson-morley.com/research/vaccine.html
[36] Cervix photo--http://www.herpes.org.nz/prgen.html
[37] Whitlow --http://www.herpes.org.nz/prbody.html
[38] Ear, labial, neck--http://www.herpes.org.nz/presentations.html
New Zealand herpes foundation
[39] Ocular-foot , superior labialis thumb http://ades.tmc.edu.tw/English/pcare/course/herpes_simplex/
[40] Facial--http://tray.dermatology.uiowa.edu/HSV-001.htm
[41] Electron images + Spot-scan Electron
Cryomicroscopy -- 3-D representation of HSV-1 capsid. Reproduced
with
permission from "Structural Biology of DNA-Containing Viruses," on the
World Wide Web:
(http://www.bcm.tmc.edu/molvir/chiu.htm got image and subunits), Copyright
©
Wah Chiu, PhD, University of California, Berkeley.
http://www.medscape.com/SCP/IIM/1997/v14.n03/m2290.hanissian/m2290.hanissian.html
[42] Perng G-C,Slanina S M, Yukht A, Drolet B S, Keleher
Jr. W,Ghiasi H, Nesburn A B, and Wechsler S L. A
Herpes
Simplex Virus Type 1 Latency Associated Transcript Mutant with Increased
Virulence and Reduced
Spontanous
Reactivation. J. Virol. 1999(Feb); 73[2], 920-929
[43] White D O and Fenner F J. Medical Virology: Fourth
Edition 1994; 19,
[44] http://www.opt.pacificu.edu/opt/viral/hsvgen.htm
[45] Bearer E L, Breakefield X O, Schuback D, Reese T
S, and LaVail. Retrograde Axonal Transport of Herpes Simplex
Virus:
Evidence for a Single Mechanism and a Role for Tegument; Unpublished. Dept.
of Pathology and Laboratory
Medicine,
Brown University.
[46] Manns. Viruses and Autoimmune Liver Disease. MPIntervirology
1993;35(1-4):108-15.
[47] Fields B N, Knipe D M, Howley P M. Reviewed in Riozman
and Sears, Fields Virology [Third Edition]. Eds.,
Lippencott-Raven,
Philiadelphia, 1996; 2231-2295.
{48] Drawings of HSV Genital locations --http://www.herpes.org.nz/doihavegh.html\
[49] Herpes Whitlow Blue back Photo --http://tray.dermatology.uiowa.edu/DIB/HSV-002.htm
[50] Palm Hand Photo --http://tray.dermatology.uiowa.edu/DIB/HSV-004.htm
[51] Congenital baby Photo --http://tray.dermatology.uiowa.edu/HSVCon01.htm
[52] Congenital Photo-- http://tray.dermatology.uiowa.edu/HSVCon02.htm
[53] Congenital Photo-- http://tray.dermatology.uiowa.edu/HSVCon05.htm
[54] Hsv movie on Desk top. Herpesvirus (entire
particle) solved by cryo-electron microscopy and image
reconstruction http://www.bocklabs.wisc.edu/herpescapsid.html
[55] Vaginal HSV2 Photo -- http://www.homestead.com/HerpesNews/HerpesPictures.html
[56] Duke University Photo --http://www.duke.edu/~clark026/main.html
[57] Electron micro 2 Photo--
http://www.ozemail.com.au/~iusti/images/cd-rom/herpes02-electron%20microsocopic%20picture%20of%20hsv.jpg
[58] March of Dimes Photo http://noah.cuny.edu/pregnancy/march_of_dimes/stds/herpesis.html
[59] Genital Herpes Photos-- www.
[60] Feyzi E, Trybala E, BergstrÖm
T, Lindahl U, and Spillman D. Structural Requirement of Heperin Sulfate
for
Interaction with Herpes Simplex Virus Type 1 Virions and Isolated Glycoprotein
C-*. JBC Online
1997;272(40):24850.
[61] Perng G-C, Slainina S M, Yukht A, Drolet B
S, Keleher Jr. W, Ghiasi H, Nesburn A B, and Wechsler S L. A Herpes
Simplex Virus Type 1 Latency-Associated Transcript Mutant with Increased
Virulence and Reduced Spontaneous
Reactivation. J. Virol Online 1999 (Feb); 73 (2): 920-929.
[62] Koelle D M, Frank J M, Johnson M L and Kwok
W W. Recogniton of Herpes Simplex Virus Type 2 Tegument
Proteins by CD4 T Cells Infiltrating Human Genital Lesions. J. Virol. 1998
(Sept.); 72[9]: 7476-7483.
[63] Jerome K R, Tait J F, Koelle D M and Corey
L. Herpes Simplex Virus Type 1 Renders Infected Cells Resistant to
Cytotoxic T-Lymphocyte-Induced Apoptosis. J. Virol.1998 (Jan). 72[1]: 436-441.
[64] Aurelian L, Kokuba H and Smith C C. Vaccine
Potential of a Herpes Simplex Virus Type 2 Mutant Deleted in the PK
Domain of the Large Subunit of Ribonucleotide Reductase (ICP10). Vaccine1999;17:
1951-1963.
[65] Lubinski J M, Wang L, Soulika A M, Burger R,
Wetsel R A, Colten G H, Eisenberg R J, Lambris J D and Freidman
H M. Herpes Simplex Virus Type 1 Glycoprotein gC Mediates Immune Evasion
In Vivo. J Virol. 1998 (Oct);72[10]:
8257-8263.
[66] Bernstein D I and Stanbery L R. Herpes Simplex
Virus Vaccines. Vaccine 1999; 17: 1681-1689.
[67] Ghiasi H, Nesburn A B and Wechsler S L. Vaccination
with a Cocktail of Seven Recombinatly exjpressed HSV-1
Glycoproteins protects against Ocular HSV-1 Challenge More Efficiently
than Vaccination with any Individual
Glycoprotein. Vaccine 1996; 14[2]: 107-112.
[68] Rosenthal K S, Mao H, Horne W I, Wright C and
Zimmerman D. Immunization with a LEAPS(TM)
Heteroconjugate Containing a CTL Epitope and a Peptide from Beta-2-microglobulin
Elicits a Protective and DTH
Response to Herpes Simplex Virus Type 1. Vaccine 1999; 17: 535-542.
[69] Bernstein D. Effect of Route of Vaccination
with Vaccinia Virus Expressing HSV-2 Glycoprotein D on Protection from
Genital HSV-2 Infection. Vaccine 2000; 18: 1351-1358
[70] O'Hagen D, Goldbeck C, Ugozzoli M, Ott
G and Burke. Intranasal Immunization with Recombinant gD2 Reduces
disease Severity and Mortality Following Genital Challenge with Herpes
Simplex Virus Type 2 in Guinea Pig Models.
Vaccine 1999; 17: 2229-2236.
[71] Corey L and Handsfield H H. Genital Herpes
and Public Health: Addressing a Global Problem. JAMA 2000 (Feb
9);283[6]:791-4.
[72] Langenberg A G, Corey L, Ashley R L,
Leong W P and Straus S E. A Prospective Study of New Infections with
Herpes Simplexvirus Type 1 and 2. Chiron HSV Vaccine Study Group. N Engl
J Med 1999(Nov); 341[19]:
1432-1438.
[73] Benencia F and Courreges M C. Antiviral
Activity of Sandalwood Oil Against Herpes Simplex Viruses-1 and-2.
Phytomedicine 1999 (May);6[2]:119-123.
[74] Hashido M and Kawana T. Herpes Simplex
Virus-Specific IgM, IgA and IgG Subclass Antibody Responses in
Primary and Nonprimary Genital Herpes Patients. Microbiol Immunol 1997;
41[5]:415-420.
[75] Ghiasi H, Hofman F M, Cai S, Perng G-C,
Nesburn A B and Wechsler S L. Vaccination with Different HSV-1
Glycoproteins Induces Different Patterns of Ocular Cytokine Responses Following
HSV-1 Challenge of Vaccinated
Mice. Vaccine 1999;17: 2576-2582.
[76] Hedner E, Vahlne A, Kahnberg K E and
Hirsch J M. Reactivated Herpes Simplex Virus Infestion as a Possible
Cause of Dry Socket After Tooth Extraction. J Oral Maxillofac Surg. 1993
(Apr); 51[4]: 370-378.
[77] Belshe R B. Textbook of Human Virology.PSG
Publishing Company,Inc. 1994: 811-821.
[78] Domingo E, Webster R and Holland J. Origin
and Evolution of Viruses. ACADEMIC PRESS 1999.
[79] White D O and Fenner F J. Medical Virology:
Fourth Edition. ACADEMIC PRESS 1994.19-38,91-272, 317-347.
[80] Booy F P, Newcomb W W, Trus B L, Brown
J C, Baker T S and Steven A C. Liquid-Crystalline,Phage-like
Packing of Encapsidated DNA in Herpes Simplex Virus. CELL 1991 (March
8); 64:1007-1015.
[81] Glorioso J C, DeLuca N A and Fink D J.
Development and Application of Herpes Simplex Virus Vectors for
Human Gene Therapy. Annu. Rev. of Microbiol. 1995; 49: 675-710.
[82] Tortora G J. Principles of Human Anatomy:
Sixth Edition. HarperCollins Publishers 1992.96,463.
Epidemiology
/ Pathogenesis / Mode_of_Infection
/ Immune_Response / Immune_Evasion
/
Pathologies
/ Treatment / Genetics
/ Vaccines / Photos
/ References / Links
/ HSV Home